Specialty pharma firm Antares Pharma (ATRS) pared down its losses in the fourth quarter due to reduced R&D expenses. The company reported a loss of $3.7 million or $0.02 per share compared to $4.4 million or $0.03 per share in the prior year period. Sales declined marginally by 1% to $14 million.
On the products front, OTREXUP sales improved 17% to $4.8 million and auto injector devices sales more than doubled to $3.1 million. Development revenues decreased to $2.2 million as products under development is getting ready for market launch. With its partner AMAG Pharmaceuticals’ Makena product getting FDA approval, the company expects its top line to improve in 2018 as AMAG uses Antares’ QuickShot auto injector.
For fiscal 2017, sales improved 4% to $54.5 million, while net loss reduced to $16.7 million compared to $24.2 million, helped by reduced expenses.
Most Popular
Can General Motors (GM) navigate the tariff challenge ahead?
General Motors' (NYSE: GM) stock tumbled last week after the Trump administration imposed new tariffs on automobile imports, raising concerns about their potential impact on the company’s production as it
What to look for when Delta Air Lines (DAL) reports its Q1 2025 earnings results
Shares of Delta Air Lines (NYSE: DAL) were down over 1% on Monday. The stock has dropped 28% over the past three months. The airline is scheduled to report its
STZ Earnings Preview: Can Constellation Brands leverage growing beer sales?
Constellation Brands, Inc. (NYSE: STZ) has effectively navigated challenges like cautious consumer spending and declining demand for its wine and spirits brands by capitalizing on the sustained growth in the
